Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Samuel Muñoz-Vicente"'
Autor:
Piers E.M. Patten, Rebecca Bishop, Andrew R. Pettitt, Christopher Fegan, Adrian Bloor, Samuel Muñoz-Vicente, Peter Hillmen, Kristian Brock, Christopher P. Fox, Rebecca H. Boucher, Andy C. Rawstron, Francesca Yates, Anna Schuh, Alison McCaig, Francesco Forconi, John G. Gribben, Talha Munir, Donald Macdonald, Stephen Devereux
Publikováno v:
Journal of Clinical Oncology
J Clin Oncol
J Clin Oncol
PURPOSE The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and replace chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a75bf26918b90f57b92a412c32516b21
http://livrepository.liverpool.ac.uk/3050113/1/jco.19.00894.pdf
http://livrepository.liverpool.ac.uk/3050113/1/jco.19.00894.pdf
Autor:
Ruth M. de Tute, Peter Hillmen, Kristian Brock, Andy C. Rawstron, Samuel Muñoz-Vicente, Walter M Gregory, Francesca Yates, Anna Chalmers, Laura Collett, Abraham M. Varghese, Rebecca Bishop, David Phillips, Lucy McParland, Talha Munir, Dena R. Howard
Publikováno v:
Blood. 128:3226-3226
Background: The detection of minimal residual disease (MRD) in CLL using a 0.01% cut-off is an independent predictor of progression-free (PFS) and overall survival (OS) after chemo-immunotherapy. There are several new treatments available and using M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d59ad5b8b6ad8911565847d88690196
https://doi.org/10.1182/blood.v128.22.3226.3226
https://doi.org/10.1182/blood.v128.22.3226.3226
Autor:
Adrian Bloor, Samuel Muñoz-Vicente, Oonagh Sheehy, Christopher Fegan, Peter Hillmen, Donald Macdonald, Stephen Devereux, Christopher P. Fox, Kristian Brock, Andy C. Rawstron, Rebecca Bishop, Francesca Yates, Andrew R. Pettitt, Ruth M. de Tute, Talha Munir, Surita Dalal
Publikováno v:
Blood. 128:2049-2049
Background: A major aim of treatment in CLL is to eradicate detectable minimal residual disease (MRD). Ibrutinib is a major step forward in the treatment of CLL but results in an immediate lymphocytosis that persists in most patients for at least sev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88fbd1003de40acc87546cbb79445d6f
https://doi.org/10.1182/blood.v128.22.2049.2049
https://doi.org/10.1182/blood.v128.22.2049.2049